Franklin Biolabs is pleased to announce the availability of AAV Neutralizing Antibody (NAb) testing for multiple serotypes in its CLIA-certified laboratory. This capability supports patient screening and provides clinically reportable results to advance gene therapy programs.
Building on its experience supporting immunogenicity and bioanalytical testing for more than 14 ongoing clinical trials from early to late phase, Franklin Biolabs continues to expand its integrated capabilities across preclinical research, bioanalysis, CMC, and clinical testing. This milestone further strengthens the company’s commitment to accelerating the development of innovative genetic medicines.
To learn more about our services, contact us today!